ES2051881T3 - Procedimiento de preparacion de un formulacion farmaceutica de liberacion prolongada. - Google Patents

Procedimiento de preparacion de un formulacion farmaceutica de liberacion prolongada.

Info

Publication number
ES2051881T3
ES2051881T3 ES88403161T ES88403161T ES2051881T3 ES 2051881 T3 ES2051881 T3 ES 2051881T3 ES 88403161 T ES88403161 T ES 88403161T ES 88403161 T ES88403161 T ES 88403161T ES 2051881 T3 ES2051881 T3 ES 2051881T3
Authority
ES
Spain
Prior art keywords
pharmaceutical formulation
prolonged release
procedure
preparation
eticellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88403161T
Other languages
English (en)
Inventor
Howard Stevens
Maryvonne Chariot
Francoise Arnold
Gareth Lewis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthelabo SA
Original Assignee
Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthelabo SA filed Critical Synthelabo SA
Application granted granted Critical
Publication of ES2051881T3 publication Critical patent/ES2051881T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FORMULACION FARMACEUTICA DE LIBERACION PROLONGADA QUE PERMITE LA DISOLUCION CONTROLADA DEL PRINCIPIO ACTIVO, INDEPENDIENTEMENTE DEL PH, CARACTERIZADO POR ESTAR FORMADO POR MICROORGANISMOS QUE CONTIENEN EL PRINCIPIO ACTIVO RECUBIERTOS POR UNA MEZ<CLA DE ETILCELULOSA Y DE EUDRAGIT RS.
ES88403161T 1987-12-21 1988-12-13 Procedimiento de preparacion de un formulacion farmaceutica de liberacion prolongada. Expired - Lifetime ES2051881T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8717855A FR2624732B1 (fr) 1987-12-21 1987-12-21 Formulation pharmaceutique a liberation prolongee

Publications (1)

Publication Number Publication Date
ES2051881T3 true ES2051881T3 (es) 1994-07-01

Family

ID=9358116

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88403161T Expired - Lifetime ES2051881T3 (es) 1987-12-21 1988-12-13 Procedimiento de preparacion de un formulacion farmaceutica de liberacion prolongada.

Country Status (23)

Country Link
US (1) US5112621A (es)
EP (1) EP0322277B1 (es)
JP (1) JPH082782B2 (es)
KR (1) KR960009650B1 (es)
AR (1) AR243378A1 (es)
AT (1) ATE71837T1 (es)
AU (1) AU609916B2 (es)
CA (1) CA1332567C (es)
DE (1) DE3868037D1 (es)
DK (1) DK172370B1 (es)
ES (1) ES2051881T3 (es)
FI (1) FI97445C (es)
FR (1) FR2624732B1 (es)
GR (1) GR3003826T3 (es)
HU (1) HU199685B (es)
IE (1) IE60313B1 (es)
IL (1) IL88736A (es)
IT (1) IT8723196A0 (es)
MX (1) MX169322B (es)
NO (1) NO179357C (es)
NZ (1) NZ227412A (es)
PT (1) PT89276B (es)
ZA (1) ZA889495B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03145418A (ja) * 1989-10-27 1991-06-20 Sumitomo Pharmaceut Co Ltd 塩基性薬物塩酸塩の徐放性製剤
EP0452862B1 (en) * 1990-04-18 1995-07-19 Asahi Kasei Kogyo Kabushiki Kaisha Spherical seed cores, spherical granules and process for production thereof
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
ZA923474B (en) * 1991-05-20 1993-01-27 Marion Merrell Dow Inc Diltiazem formulation
US5288505A (en) * 1991-06-26 1994-02-22 Galephar P.R., Inc., Ltd. Extended release form of diltiazem
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
GB2258613B (en) * 1991-08-12 1996-01-10 Euro Celtique Sa Pharmaceutical diltiazem formulation
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US7070806B2 (en) * 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5837277A (en) * 1992-06-04 1998-11-17 Smithkline Beecham Corporation Palatable pharmaceutical compositions
WO1993024109A1 (en) * 1992-06-04 1993-12-09 Smithkline Beecham Corporation Palatable pharmaceutical compositions
US5376384A (en) * 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
JP3264722B2 (ja) * 1993-02-25 2002-03-11 第一製薬株式会社 カプセル製剤
US5834024A (en) * 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
FR2742660B1 (fr) 1995-12-22 1998-04-03 Ethypharm Lab Prod Ethiques Nouvelles formes de microgranules a liberation prolongee contenant du diltiazem comme principe actif
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
US5830503A (en) * 1996-06-21 1998-11-03 Andrx Pharmaceuticals, Inc. Enteric coated diltiazem once-a-day formulation
PT1009387E (pt) 1997-07-02 2006-08-31 Euro Celtique Sa Formulacoes estabilizadas de libertacao controlada de tramadol
ME00189B (me) * 1998-03-26 2011-02-10 Astellas Pharma Inc Preparati sa neprekidnim oslobađanjem
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
UA67802C2 (uk) 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
GB9825988D0 (en) * 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
US6635277B2 (en) 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
GB0018968D0 (en) * 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
US6663896B1 (en) 2001-08-01 2003-12-16 Alvin S. Blum Delayed release aspirin for vascular obstruction prophylaxis
KR100407519B1 (ko) * 2001-08-31 2003-12-18 부광약품 주식회사 건조황산제일철과 방출조절제로서 엘-글루타민을 함유하는서방성 정제 및 그의 제조방법
KR100446818B1 (ko) * 2001-11-06 2004-09-01 김재윤 질산 이소소르비드 서방성 펠렛 제형
ES2405404T3 (es) * 2003-10-29 2013-05-31 Wyeth Llc Composiciones farmacéuticas de liberación sostenida que comprenden aplindore y sus derivados
EP1730516A1 (en) * 2004-03-30 2006-12-13 Pfizer Products Incorporated Method and device for evaluation of pharmaceutical compositions
KR100775957B1 (ko) * 2006-02-07 2007-11-13 경상대학교산학협력단 애기장대 유래의 개화시기를 조절 단백질 ｃｏ의 돌연변이단백질, 상기 단백질을 이용한 식물의 개화시기 조절전사인자의 분리방법 및 식물의 개화시기 조절방법
CN100442981C (zh) * 2006-11-09 2008-12-17 广东省昆虫研究所 一种德国小蠊毒饵
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
WO2008125940A2 (en) * 2007-04-17 2008-10-23 Pfizer Products Inc. Nanoparticles comprising non-crystalline drug
WO2008135852A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Pharmaceutical compositions comprising nanoparticles and casein
US8309129B2 (en) * 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8703204B2 (en) * 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
EP2162120B1 (en) * 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
WO2009073216A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer
EP2231169B1 (en) * 2007-12-06 2016-05-04 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
EP2550863A1 (de) * 2011-07-27 2013-01-30 Bayer Intellectual Property GmbH Aktivstoffhaltige Partikel auf Polyacrylat-Basis
KR102085557B1 (ko) 2013-03-14 2020-03-06 엘커메스 파마 아일랜드 리미티드 푸마레이트의 프로드럭 및 다양한 질환을 치료하는데 있어서의 이들의 용도
CA2936740C (en) 2014-10-31 2017-10-10 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
KR101639163B1 (ko) * 2015-07-08 2016-07-22 울산대학교 산학협력단 저전송 영상 정보 및 센싱 정보 송수신 장치 및 이의 동작 방법
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU187215B (en) * 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
US4533674A (en) * 1983-10-24 1985-08-06 Basf Wyandotte Corporation Process for preparing a sugar and starch free spray-dried vitamin C powder containing 90 percent ascorbic acid
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
JPH0625055B2 (ja) * 1985-03-18 1994-04-06 日本ケミフア株式会社 持続性錠剤
JPS625915A (ja) * 1985-07-03 1987-01-12 Nippon Iyakuhin Kogyo Kk 塩酸ジルチアゼム徐放性製剤及びその製法
US4775536A (en) * 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions

Also Published As

Publication number Publication date
IE883810L (en) 1989-06-21
HU199685B (en) 1990-03-28
IL88736A (en) 1992-11-15
DK708088A (da) 1989-06-29
HUT49290A (en) 1989-09-28
IT8723196A0 (it) 1987-12-23
PT89276B (pt) 1993-12-31
DK708088D0 (da) 1988-12-20
FR2624732A1 (fr) 1989-06-23
FI885884A0 (fi) 1988-12-20
NO179357C (no) 1996-09-25
FI97445C (fi) 1996-12-27
CA1332567C (en) 1994-10-18
ZA889495B (en) 1989-09-27
GR3003826T3 (es) 1993-03-16
NO885641L (no) 1989-06-22
US5112621A (en) 1992-05-12
DK172370B1 (da) 1998-04-27
AR243378A1 (es) 1993-08-31
IL88736A0 (en) 1989-07-31
MX169322B (es) 1993-06-29
EP0322277B1 (fr) 1992-01-22
KR960009650B1 (en) 1996-07-23
FI885884L (fi) 1989-06-22
IE60313B1 (en) 1994-06-29
NZ227412A (en) 1989-12-21
KR890009380A (ko) 1989-08-01
FI97445B (fi) 1996-09-13
ATE71837T1 (de) 1992-02-15
JPH02202A (ja) 1990-01-05
DE3868037D1 (de) 1992-03-05
NO179357B (no) 1996-06-17
AU2707788A (en) 1989-06-22
NO885641D0 (no) 1988-12-20
JPH082782B2 (ja) 1996-01-17
EP0322277A1 (fr) 1989-06-28
PT89276A (pt) 1989-12-29
FR2624732B1 (fr) 1991-02-15
AU609916B2 (en) 1991-05-09

Similar Documents

Publication Publication Date Title
ES2051881T3 (es) Procedimiento de preparacion de un formulacion farmaceutica de liberacion prolongada.
ES2159591T3 (es) Composicion de liberacion controlada.
ES2042541T3 (es) Un procedimiento de preparacion de una formulacion farmaceutica de liberacion retardada que contiene goma de xantano.
ES2074124T5 (es) Composicion en forma de una espuma que contiene acido 5-aminosalicilico para administracion intra-rectal.
ES2060593T3 (es) Sistema de aporte de farmacos.
DE3778223D1 (de) Biologisch erodierbares system mit gesteuerter freisetzung des arzneiwirkstoffes.
SE8703034L (sv) Oralt terapeutiskt system med systemisk verkan
DE3880593D1 (de) Arzneizubereitungen mit retardierter wirkstofffreisetzung.
PT88945A (pt) Processo para a preparacao de formas de dosagem farmaceuticas de libertacao controlada contendo um antagonista do calcio, tal como cloridrato de diltiazem
DE69000881D1 (de) 2-propylvaleriansaeure enthaltende arzneizubereitung mit verzoegerter wirkstofffreigabe.
DE3879853D1 (de) Klebstoffzusammensetzung, zusammensetzung mit kontrollierter wirkstofffreisetzung und system zur transdermalen anwendung von arzneien.
ES2094539T3 (es) Preparacion farmaceutica y procedimiento para su preparacion.
ZA955547B (en) Multiple unit pharmaceutical preparation
CO5580776A2 (es) Formulacion farmaceutica estable en solucion de oxaliplatino
DK0436370T3 (da) Farmaceutisk præparat til kontrolleret afgivelse og fremgangsmåde til fremstilling deraf
ATE87471T1 (de) Eine fluessige verabreichungsform fuer orale verabreichung einer pharmazeutischen substanz.
DE68909772D1 (de) Diclofenac-Natrium-Arzneizubereitung mit verlängerter Wirkstoffabgabe.
IS3284A7 (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
DE19475001I2 (de) Anthelminthische Wirkstoffkombinationen.
HRP20010684B1 (hr) Izravno stlaciva matrica za kontrolirano otpustanje jednostruke dnevne doze klaritromicina
ATE38151T1 (de) Bestaendige 5-adenosyl-l-methionin-salze enthaltende, pharmazeutische zusammensetzungen fuer orale anwendung.
MX9305143A (es) Composiciones nutritivas o medicamentos a base de quitosana, para la administracion de los rumiantes y procedimiento para su preparacion.
ATE295157T1 (de) Mittel zur transdermalen verabreichung von arzneistoffen
EE9600202A (et) Toimeaine pärsitud vabanemisega karbamasepiini ravimvorm
DE58903964D1 (de) Fluessige orale formulierung.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 322277

Country of ref document: ES